Complete sequence of p53 gene in 20 patients with lung cancer: comparison with chemosensitivity and immunohistochemistry
In this study the entirep53 complementary DNA has been sequenced in 20 non-small cell lung carcinomas (NSCLC) and the results correlated with chemosensitivity, immunohistochemistry and clinical data. Ten patients had mutations inp53, 8 missense mutations and 2 nonsense mutations. The method discovered two mutations never described previously and two other mutations that have never been described before in connection with NSCLC tumours. Chemosensitivity data, according to a short-term assay (FMCA), indicated that tumours with p53 mutation were more resistant to cisplatin and cyclophosphamide. Immunohistochemical studied demonstrated a 70% concordance between over-expression of p53 protein and mutation inp53. No conclusions or trends could be drawn from the immunohistochemical studies ofBcl-2 andBax.
Keywordsp53 Bax Bcl-2 immunohistochemistry drug resistance mutation cDNA sequencing ALFexpress non-small cell lung cancer NSCLC
Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene.Nature
: 453–456.PubMedCrossRefGoogle Scholar
Takahashi Tet al.
p53: a frequent target for genetic abnormalities in lung cancer.Science
: 491–494.PubMedCrossRefGoogle Scholar
Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations [see comments].Science
: 346–355.PubMedCrossRefGoogle Scholar
Ory K, Legros Y, Auguin C, Soussi T. Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation.EMBO J
: 3496–3504.PubMedGoogle Scholar
Williams Cet al.
Assessment of sequence-based p53 gene analysis in human breast cancer: messenger RNA in comparison with genomic DNA targets.Clin Chem
: 455–462.PubMedGoogle Scholar
Kawasaki Met al.
p53 immunostaining predicts chemiosensitivity in non-small cell lung cancer: a preliminary report.Cancer J Sci Am
: 217.PubMedGoogle Scholar
Rusch Vet al.
: Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer.Cancer Res
: 5038–5042.PubMedGoogle Scholar
Fujiwara Tet al.
Induction of chemosensitivity in human lung cancer cellsin vivo
by adenovirus-mediated transfer of the wild-type p53 gene.Cancer Res
: 2287–2291.PubMedGoogle Scholar
Elledge RM. Assessing p53 status in breast cancer prognosis: where should you put the thermometer if you think your p53 is sick? [editorial].J Natl Cancer Inst
: 141–143.PubMedCrossRefGoogle Scholar
Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 hetero-dimerizesin vivo
with a conserved homolog, Bax, that accelerates programmed cell death.Cell
: 609–619.PubMedCrossRefGoogle Scholar
White E. Life, death, and the pursuit of apoptosis.Genes Dev
: 1–15.PubMedCrossRefGoogle Scholar
Gascoyne RD, Krajewska M, Krajewski S, Connors JM, Reed JC. Prognostic significance of Bax protein expression in diffuse aggressive non-Hodgkin's lymphoma.Blood
: 3173–3178.PubMedGoogle Scholar
Marx Det al.
Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer.Anticancer Res
: 2233–2240.PubMedGoogle Scholar
Apolinario RMet al.
Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small cell lung cancer.J Clin Oncol
: 2456–2466.PubMedGoogle Scholar
Sjogren Set al.
The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.J Natl Cancer Inst
: 173–182.PubMedCrossRefGoogle Scholar
Larsson R, Nygren P. Pharmacological modification of multi-drug resistance (MDR)in vitro
detected by a novel fluorometric microculture cytotoxicity assay. Reversal of resistance and selective cytotoxic actions of cyclosporin A and verapamil on MDR leukemia T-cells.Int J Cancer
: 67–72.PubMedCrossRefGoogle Scholar
Nygren Pet al.
Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia.Leukemia
: 1121–1128.PubMedGoogle Scholar
Cattoretti Get al.
Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections [see comments].J Pathol
: 83–98.PubMedCrossRefGoogle Scholar
Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53.J Immunol Methods
: 237–244.PubMedCrossRefGoogle Scholar
Cariello NF, Beroud C, Soussi T. Database and software for the analysis of mutations at the human p53 gene.Nucleic Acids Res
: 3549–3550.PubMedGoogle Scholar
Jansson Tet al.
p53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings.J Clin Oncol
: 2745–2751.PubMedGoogle Scholar
Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy.Nat Med
: 1029–1034.PubMedCrossRefGoogle Scholar
Kressner U. Prognostic markers in colorectal cancer: aspects of proliferation, tumour stroma and genetic changes [Dissertation from the Faculty of Medicine 718.]. Uppsala University: Uppsala, 1997, 60 p.Google Scholar
Winter SFet al.
Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.Cancer Res
: 4168–4174.PubMedGoogle Scholar
Bergqvist Met al.
p53 auto-antibodies in non-small cell lung cancer patients, can predict increased life expectancy after radiotherapy.Anticancer Res
: 1999–2002.PubMedGoogle Scholar
Lee JSet al.
Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor.J Clin Oncol
: 1893–1903.PubMedGoogle Scholar
Prives C. How loops, beta sheets, and alpha helices help us to understand p53.Cell
: 543–546.PubMedCrossRefGoogle Scholar
Lin J, Chen J, Elenbaas B, Levine AJ. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.Genes Dev
: 1235–1246.PubMedCrossRefGoogle Scholar
Egle Aet al.
Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status.Br J Haematol
: 418–428.PubMedCrossRefGoogle Scholar